Inhibikase Therapeutics, Inc. (IKT) Dividend History

Inhibikase Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing kinase inhibitors for the treatment of neurodegenerative and infectious diseases. The company's approach involves targeting aberrant kinase activity involved in disease progression, aiming to create therapies with improved safety and efficacy profiles. Founded with an emphasis on precision medicine, Inhibikase leverages its expertise in kinase biology to advance novel therapeutic candidates.

3350 Riverwood Parkway Se, Suite 1900, Atlanta, GA, 30339
Phone: 678-392-3419
Website: https://www.inhibikase.com

Dividend History

Inhibikase Therapeutics, Inc. currently does not pay dividends

Company News

Top 10 Small-Cap Stocks to Watch in 2025

The article discusses 10 small-cap stocks that could outperform in 2025, citing factors like falling interest rates, low valuations, and potential shifts in industrial production.

Investing.com

Featured Companies: AUNA CNTX CRGO EVGO FFIC IRD OKLO PENG WOLF
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease

Company expects to report trial results in 4Q24 Company expects to report trial results in 4Q24

GlobeNewswire Inc.
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

- Company positioning multiple assets for late-stage development across its therapeutic pipeline –

GlobeNewswire Inc.
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,672,452 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered Series A warrants to purchase up to an aggregate of 1,672,452 shares of common stock, and unregistered Class B warrants to purchase up to an aggregate of 1,672,452 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold with one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock at a combined purchase price of $1.68. The Series A and Series B warrants will each have an exercise price of $1.68 per share, will be exercisable beginning on the effective date of stockholder approval and, in the case of Series A warrants, will expire on the one-year anniversary from the date of stockholder approval, and in the case of Series B warrants, will expire on the five-year anniversary from the date of stockholder approval.

GlobeNewswire Inc.
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 20:08:11 UTC